"Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an in Vivo Evaluation of the Molecular Effects on β-catenin Signaling Pathway."
PHASE2CompletedINTERVENTIONAL
Enrollment
21
Participants
Timeline
Start Date
October 31, 2012
Primary Completion Date
June 30, 2016
Study Completion Date
June 30, 2016
Conditions
Colorectal Cancer
Interventions
DRUG
Mesalazine
Mesalazine cpr 800 mg t.i.d. for 3 months
Trial Locations (1)
26100
Istituti Ospitalieri di Cremona, Cremona
All Listed Sponsors
lead
SOFAR S.p.A.
INDUSTRY
NCT02077777 - "Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an in Vivo Evaluation of the Molecular Effects on β-catenin Signaling Pathway." | Biotech Hunter | Biotech Hunter